PATENT CLAIM ANALYSIS

Application Number: 16085861
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "04400R"]

Abstract:
It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Claim (Index 6):
The pharmaceutical composition according to  claim 5 , characterized in that the molar ratio of the ribonucleic acid aptamer to the epirubicin in the adduct is 1:(4-12).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.84
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15755958', '14411176', '15500345', '13876111', '15500354']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7890896730487609
- 35 USC 102 Novelty (BERT): 0.5175660072441471
- Combined Prediction Score: 0.7619373064682995
- Mean Citation Score: 274.036032
- Max Citation Score: 299.6154
- Similarity Product: 208.25697051701545

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test